Trinconi Cunha Mateus, Wallace Neil, Porceddu Sandro, Ferrarotto Renata
Division of Thoracic and Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Department of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Cancer. 2025 Jun 1;131(11):e35920. doi: 10.1002/cncr.35920.
Antibodies against PD-1 (PD1i), such as cemiplimab and pembrolizumab, have demonstrated significant efficacy in advanced, unresectable cutaneous squamous cell carcinoma (cSCC). These agents elicit durable responses in approximately 45% of patients, contributing to improved aesthetic, functional, and survival outcomes in a subset of individuals with advanced cSCC. This review highlights recent and ongoing research investigating the safety and efficacy of immune checkpoint inhibitors for cSCC in the curative intent perioperative settings, advanced/metastatic setting, and within the immunocompromised patient populations.
抗程序性死亡蛋白1（PD-1）抗体（PD1i），如西米普利单抗和帕博利珠单抗，已在晚期、不可切除的皮肤鳞状细胞癌（cSCC）中显示出显著疗效。这些药物在约45%的患者中引发持久反应，有助于改善一部分晚期cSCC患者的美观、功能和生存结局。本综述重点介绍了近期和正在进行的研究，这些研究探讨了免疫检查点抑制剂在cSCC的根治性围手术期、晚期/转移性以及免疫功能低下患者群体中的安全性和疗效。
Zotero 插件